Business Segment, Geographic, and Concentration Risk Information (Tables)

9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Summary of Revenue by Segments

Segment information is as follows (in thousands):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Total revenue:
Oncology Innovation Platform	$	115		$	5,117		$	421		$	30,532
Global Supply Chain Platform		7,969			7,092			30,714			17,991
Commercial Platform		12,006			7,315			38,279			23,006
Total revenue for reportable segments		20,090			19,524			69,414			71,529
Intersegment revenue		(726	)		(1,096	)		(2,546	)		(3,700	)
Total consolidated revenue	$	19,364		$	18,428		$	66,868		$	67,829

Summary of Revenue by Product Group

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Total revenue by product group:
API sales	$	3,647	$	3,690	$	12,308	$	9,538
Medical device sales		—		1,322		—		2,342
Contract manufacturing revenue		93		17		382		412
Commercial product sales		15,497		8,280		53,743		25,092
License fees		—		5,000		—		30,000
Other revenue		127		119		435		445
Total consolidated revenue	$	19,364	$	18,428	$	66,868	$	67,829

Summary of Segment Information

	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Net loss attributable to Athenex, Inc.:
Oncology Innovation Platform	$	(29,732	)	$	(37,638	)	$	(87,127	)	$	(65,985	)
Global Supply Chain Platform		(3,376	)		(6,089	)		(3,829	)		(16,780	)
Commercial Platform		(1,650	)		(2,443	)		(11,066	)		(7,562	)
Total consolidated net loss attributable to    Athenex, Inc.	$	(34,758	)	$	(46,170	)	$	(102,022	)	$	(90,327	)

Summary of Depreciation, Amortization and Assets by Segment

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Total depreciation and amortization:
Oncology Innovation Platform	$	227	$	174	$	626	$	505
Global Supply Chain Platform		376		490		1,012		1,185
Commercial Platform		398		245		1,170		734
Total consolidated depreciation and    amortization	$	1,001	$	909	$	2,808	$	2,424

	September 30,		December 31,
	2019		2018
Total assets:
Oncology Innovation Platform	$	174,938	$	135,878
Global Supply Chain Platform		65,833		58,816
Commercial Platform		46,824		36,401
Total consolidated assets	$	287,595	$	231,095

Summary of Revenue by Geographical Segment

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Total revenue:
United States	$	15,624	$	9,559	$	54,119	$	27,405
India		1,684		259		3,066		1,701
China		563		306		1,837		1,917
South Korea		513		—		513		—
Austria		476		2,227		4,423		5,102
Germany		398		—		602		—
United Kingdom		—		—		1,023		—
Spain		—		5,000		—		30,000
Other foreign countries		106		1,077		1,285		1,704
Total consolidated revenue	$	19,364	$	18,428	$	66,868	$	67,829

Summary of Property and Equipment by Geographical Segment

	September 30,		December 31,
	2019		2018
Total property and equipment, net:
United States	$	10,791	$	6,549
China		8,481		4,898
Total consolidated property and equipment, net	$	19,272	$	11,447

Summary of Customer Revenue and Accounts Receivable Concentration

Customer revenue and accounts receivable concentration amounted to the following for the identified periods. These customers relate to the Commercial Platform segment and the Global Supply Chain Platform segment.

	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Percentage of total revenue by customer:
Customer A		17	%		12	%		20	%		13	%
Customer B		22	%		11	%		17	%		8	%
Customer C		17	%		13	%		16	%		9	%
Customer D		—			27	%		—			44	%
Customer E		2	%		10	%		6	%		6	%

	September 30,			December 31,
	2019			2018
Percentage of total accounts receivable by customer:
Customer A		40	%		16	%
Customer B		35	%		18	%
Customer C		10	%		12	%